Tags

Type your tag names separated by a space and hit enter

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Vaccine. 2014 Jun 05; 32(27):3452-9.V

Abstract

BACKGROUND

The 7-valent pneumococcal conjugated vaccine (PCV7) was introduced to the Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 months), with a fast reduction of invasive pneumococcal disease (IPD) caused by PCV7 serotypes. Starting in November 2010, PCV13 gradually replaced PCV7.

AIM

To report the impact of PCV7/PCV13 sequential introduction on IPD in Israeli children <5 years.

METHODS

An ongoing nationwide, prospective, population-based, active surveillance. All IPD episodes (Streptococcus pneumoniae isolated from blood and/or cerebrospinal fluid) from July 2004 through June 2013 were included.

RESULTS

Overall, 2670 IPD episodes were recorded. Incidence of IPD caused by PCV7+6A serotypes during the PCV13 period vs. pre-PCV period decreased by 95% (Incidence Rate Ratio [IRR]=0.05; 95% CI=0.03-0.09). This reduction was observed in a two-step manner: 90% in the PCV7-period and further 5% in the PCV13-period. The rates of IPD caused by the 5 additional PCV13-serotypes (1, 3, 5, 7F, 19A; 5VT) increased initially by 47%, but subsequently decreased by 79%, resulting in an overall 70% reduction during the entire study period (IRR=0.30; 0.21-0.44). A two-fold increase in non-PCV13 serotypes IPD was observed (IRR=2.43; 1.73-3.66). In total, a 63% reduction of all-serotype IPD episodes was observed in children <5 years (69% and 48% in children <2 and 2-4 years old, respectively).

CONCLUSIONS

After initiation of PCV NIP, a rapid and substantial 2-step IPD reduction was observed in children <5 years. The serotype-specific rate reduction reflected the sequential introduction of PCV7/PCV13.

Authors+Show Affiliations

The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel.The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel.The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel.Shaare Zedek Medical Center, Jerusalem, Israel.Wolfson Medical Center, Holon, Israel.The Barzilai Medical Center, Ashkelon, Israel.The Pediatric Infectious Disease Service, HaEmek Medical Center, Afula, Israel.The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel. Electronic address: rdagan@bgu.ac.il.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24690148

Citation

Ben-Shimol, Shalom, et al. "Early Impact of Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccine On IPD in Israeli Children <5 Years: an Active Prospective Nationwide Surveillance." Vaccine, vol. 32, no. 27, 2014, pp. 3452-9.
Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452-9.
Ben-Shimol, S., Greenberg, D., Givon-Lavi, N., Schlesinger, Y., Somekh, E., Aviner, S., Miron, D., & Dagan, R. (2014). Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine, 32(27), 3452-9. https://doi.org/10.1016/j.vaccine.2014.03.065
Ben-Shimol S, et al. Early Impact of Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccine On IPD in Israeli Children <5 Years: an Active Prospective Nationwide Surveillance. Vaccine. 2014 Jun 5;32(27):3452-9. PubMed PMID: 24690148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. AU - Ben-Shimol,Shalom, AU - Greenberg,David, AU - Givon-Lavi,Noga, AU - Schlesinger,Yechiel, AU - Somekh,Eli, AU - Aviner,Shraga, AU - Miron,Dan, AU - Dagan,Ron, Y1 - 2014/03/30/ PY - 2014/01/09/received PY - 2014/03/06/revised PY - 2014/03/10/accepted PY - 2014/4/3/entrez PY - 2014/4/3/pubmed PY - 2014/12/15/medline KW - Children KW - Invasive pneumococcal disease (IPD) KW - Pneumococcal conjugate vaccine (PCV) KW - Surveillance SP - 3452 EP - 9 JF - Vaccine JO - Vaccine VL - 32 IS - 27 N2 - BACKGROUND: The 7-valent pneumococcal conjugated vaccine (PCV7) was introduced to the Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 months), with a fast reduction of invasive pneumococcal disease (IPD) caused by PCV7 serotypes. Starting in November 2010, PCV13 gradually replaced PCV7. AIM: To report the impact of PCV7/PCV13 sequential introduction on IPD in Israeli children <5 years. METHODS: An ongoing nationwide, prospective, population-based, active surveillance. All IPD episodes (Streptococcus pneumoniae isolated from blood and/or cerebrospinal fluid) from July 2004 through June 2013 were included. RESULTS: Overall, 2670 IPD episodes were recorded. Incidence of IPD caused by PCV7+6A serotypes during the PCV13 period vs. pre-PCV period decreased by 95% (Incidence Rate Ratio [IRR]=0.05; 95% CI=0.03-0.09). This reduction was observed in a two-step manner: 90% in the PCV7-period and further 5% in the PCV13-period. The rates of IPD caused by the 5 additional PCV13-serotypes (1, 3, 5, 7F, 19A; 5VT) increased initially by 47%, but subsequently decreased by 79%, resulting in an overall 70% reduction during the entire study period (IRR=0.30; 0.21-0.44). A two-fold increase in non-PCV13 serotypes IPD was observed (IRR=2.43; 1.73-3.66). In total, a 63% reduction of all-serotype IPD episodes was observed in children <5 years (69% and 48% in children <2 and 2-4 years old, respectively). CONCLUSIONS: After initiation of PCV NIP, a rapid and substantial 2-step IPD reduction was observed in children <5 years. The serotype-specific rate reduction reflected the sequential introduction of PCV7/PCV13. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/24690148/Early_impact_of_sequential_introduction_of_7_valent_and_13_valent_pneumococcal_conjugate_vaccine_on_IPD_in_Israeli_children_<5_years:_an_active_prospective_nationwide_surveillance_ DB - PRIME DP - Unbound Medicine ER -